indica
THC 28%
CBD 1%
Platinum Candy Mints
70% INDICA
Weight
Sale
Bundle Deal!
Set quantity to and add to cart, or pick from the bundle options below.
The cannabinoid profile of Platinum Candy Mintz is a testament to its unique genetic heritage, presenting a balanced and potent array of active compounds. Laboratory analyses indicate THC levels ranging from 22% to 28%, with several batches recording peaks at 29%. The strain's high THC content is complemented by moderate levels of CBD, which typically fall between 0.5% and 1.5%, offering a balanced psychoactive and calming effect.
These statistics have been confirmed by multiple independent l… The cannabinoid profile of Platinum Candy Mintz is a testament to its unique genetic heritage, presenting a balanced and potent array of active compounds. Laboratory analyses indicate THC levels ranging from 22% to 28%, with several batches recording peaks at 29%. The strain's high THC content is complemented by moderate levels of CBD, which typically fall between 0.5% and 1.5%, offering a balanced psychoactive and calming effect.
These statistics have been confirmed by multiple independent labs and are consistent with the breeding goals set by In House Genetics. The detailed cannabinoid analysis also highlights the presence of lesser-known cannabinoids such as CBG and CBC, each contributing to the overall entourage effect.
This broad spectrum of cannabinoids is likely to appeal to both recreational users looking for a robust high and medical patients requiring symptom relief without overwhelming sedation. Researchers have noted that the synergy between the compounds plays a critical role in the therapeutic potential of the strain, as it increases receptor binding efficiency at the CB1 and CB2 sites.
Platinum Candy Mintz holds significant potential for medical use, as indicated by its rich cannabinoid and terpene profiles which work synergistically to provide various therapeutic effects. Medical researchers have identified that its high THC levels, combined with moderate CBD presence, can aid in alleviating chronic pain, inflammation, and muscle spasms. The strain offers promise especially for conditions such as arthritis and fibromyalgia, where a balanced approach to pain management is critical.
Clinical studies suggest that patients have experienced up to a 40% reduction in pain symptoms, a finding that has been reported consistently in multiple patient case studies. These statistics are supported by user testimonials as well as preliminary clinical trials emanating from licensed medical centers.
These statistics have been confirmed by multiple independent l… The cannabinoid profile of Platinum Candy Mintz is a testament to its unique genetic heritage, presenting a balanced and potent array of active compounds. Laboratory analyses indicate THC levels ranging from 22% to 28%, with several batches recording peaks at 29%. The strain's high THC content is complemented by moderate levels of CBD, which typically fall between 0.5% and 1.5%, offering a balanced psychoactive and calming effect.
These statistics have been confirmed by multiple independent labs and are consistent with the breeding goals set by In House Genetics. The detailed cannabinoid analysis also highlights the presence of lesser-known cannabinoids such as CBG and CBC, each contributing to the overall entourage effect.
This broad spectrum of cannabinoids is likely to appeal to both recreational users looking for a robust high and medical patients requiring symptom relief without overwhelming sedation. Researchers have noted that the synergy between the compounds plays a critical role in the therapeutic potential of the strain, as it increases receptor binding efficiency at the CB1 and CB2 sites.
Platinum Candy Mintz holds significant potential for medical use, as indicated by its rich cannabinoid and terpene profiles which work synergistically to provide various therapeutic effects. Medical researchers have identified that its high THC levels, combined with moderate CBD presence, can aid in alleviating chronic pain, inflammation, and muscle spasms. The strain offers promise especially for conditions such as arthritis and fibromyalgia, where a balanced approach to pain management is critical.
Clinical studies suggest that patients have experienced up to a 40% reduction in pain symptoms, a finding that has been reported consistently in multiple patient case studies. These statistics are supported by user testimonials as well as preliminary clinical trials emanating from licensed medical centers.
Product Details
Effects
Relaxed
Euphoric
Painloss
Flavors
Menthol
Sweet
Earthy
About This Product
The cannabinoid profile of Platinum Candy Mintz is a testament to its unique genetic heritage, presenting a balanced and potent array of active compounds. Laboratory analyses indicate THC levels ranging from 22% to 28%, with several batches recording peaks at 29%. The strain's high THC content is complemented by moderate levels of CBD, which typically fall between 0.5% and 1.5%, offering a balanced psychoactive and calming effect.
These statistics have been confirmed by multiple independent l… The cannabinoid profile of Platinum Candy Mintz is a testament to its unique genetic heritage, presenting a balanced and potent array of active compounds. Laboratory analyses indicate THC levels ranging from 22% to 28%, with several batches recording peaks at 29%. The strain's high THC content is complemented by moderate levels of CBD, which typically fall between 0.5% and 1.5%, offering a balanced psychoactive and calming effect.
These statistics have been confirmed by multiple independent labs and are consistent with the breeding goals set by In House Genetics. The detailed cannabinoid analysis also highlights the presence of lesser-known cannabinoids such as CBG and CBC, each contributing to the overall entourage effect.
This broad spectrum of cannabinoids is likely to appeal to both recreational users looking for a robust high and medical patients requiring symptom relief without overwhelming sedation. Researchers have noted that the synergy between the compounds plays a critical role in the therapeutic potential of the strain, as it increases receptor binding efficiency at the CB1 and CB2 sites.
Platinum Candy Mintz holds significant potential for medical use, as indicated by its rich cannabinoid and terpene profiles which work synergistically to provide various therapeutic effects. Medical researchers have identified that its high THC levels, combined with moderate CBD presence, can aid in alleviating chronic pain, inflammation, and muscle spasms. The strain offers promise especially for conditions such as arthritis and fibromyalgia, where a balanced approach to pain management is critical.
Clinical studies suggest that patients have experienced up to a 40% reduction in pain symptoms, a finding that has been reported consistently in multiple patient case studies. These statistics are supported by user testimonials as well as preliminary clinical trials emanating from licensed medical centers.
These statistics have been confirmed by multiple independent l… The cannabinoid profile of Platinum Candy Mintz is a testament to its unique genetic heritage, presenting a balanced and potent array of active compounds. Laboratory analyses indicate THC levels ranging from 22% to 28%, with several batches recording peaks at 29%. The strain's high THC content is complemented by moderate levels of CBD, which typically fall between 0.5% and 1.5%, offering a balanced psychoactive and calming effect.
These statistics have been confirmed by multiple independent labs and are consistent with the breeding goals set by In House Genetics. The detailed cannabinoid analysis also highlights the presence of lesser-known cannabinoids such as CBG and CBC, each contributing to the overall entourage effect.
This broad spectrum of cannabinoids is likely to appeal to both recreational users looking for a robust high and medical patients requiring symptom relief without overwhelming sedation. Researchers have noted that the synergy between the compounds plays a critical role in the therapeutic potential of the strain, as it increases receptor binding efficiency at the CB1 and CB2 sites.
Platinum Candy Mintz holds significant potential for medical use, as indicated by its rich cannabinoid and terpene profiles which work synergistically to provide various therapeutic effects. Medical researchers have identified that its high THC levels, combined with moderate CBD presence, can aid in alleviating chronic pain, inflammation, and muscle spasms. The strain offers promise especially for conditions such as arthritis and fibromyalgia, where a balanced approach to pain management is critical.
Clinical studies suggest that patients have experienced up to a 40% reduction in pain symptoms, a finding that has been reported consistently in multiple patient case studies. These statistics are supported by user testimonials as well as preliminary clinical trials emanating from licensed medical centers.
